Is the System Rigged Against Biosimilars?
If you think prescription drug costs are high now, imagine what costs would be without generic drugs. Roughly 25% of total prescription drug sales in 2016 were generics. But it's a different story altogether for biologics -- drugs made from living organisms or components of living organisms. Until 2010, biosimilars to biologics weren't even legally allowed in the U.S.
Seven years later, biosimilars still haven't made a huge dent in helping control soaring drug costs in therapeutic categories like autoimmune diseases, where biologics dominate. Could it be that the system is rigged against biosimilars?
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Stock
€26.14
1.100%
The stock is one of the favorites of our community with 31 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a very positive potential of 56.88% compared to the current price of 26.14 € for Pfizer Inc..
